Session Title: A New Era for Patients with C3G: Redefining Standard of Care
Organized by: Novartis Pharma AG
Session Description:
At the WCN 2026 Symposium, “A New Era for Patients with C3G: Redefining Standard of Care,” leading experts will discuss the current challenges in diagnosing and managing complement 3 glomerulopathy (C3G). The session will highlight recent therapeutic advances and explore the impact of approved treatments through real-world case studies. A dynamic panel will discuss evolving guidelines and the role of emerging therapies in redefining the standard of care, followed by a brief and interactive audience Q&A. The chair will then summarize and formally close the session.
Learning Objectives:
1. Understand current challenges in diagnosing and managing C3G patients
2. Review the latest therapeutic advances in C3G, addressing the pathophysiology of the disease
3. Assess the impact of approved treatments in clinical practice, leveraging real-world case studies based on different patient profiles
4. Discuss the implication of emerging therapies in redefining standard of care
| Time | Session |
|---|---|
|
12:50 p.m.
12:55 p.m.
|
|
|
12:55 p.m.
1:15 p.m.
|
|
|
1:15 p.m.
1:35 p.m.
|
|
|
1:35 p.m.
1:45 p.m.
|